SCHEMBL3034663

SCHEMBL3034663

CCC1(O)CCN(CCCn2c(=O)[nH]c3ccccc32)CC1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.65
HTR7 P34969 7/20 0.61
P2RX7 Q99572 7/20 0.59
MEN1 O00255 1/20 0.57
MLNR O43193 1/20 0.57
NR1I2 O75469 1/20 0.57
CYP1A2 P05177 1/20 0.57
CHRM2 P08172 1/20 0.57
CYP3A4 P08684 1/20 0.57
ADORA3 P0DMS8 1/20 0.57
CYP2D6 P10635 1/20 0.57
CHRM1 P11229 1/20 0.57
CYP2C9 P11712 1/20 0.57
DRD2 P14416 1/20 0.57
PKM P14618 1/20 0.57
ADRA2C P18825 1/20 0.57
CHRM3 P20309 1/20 0.57
SLC6A2 P23975 1/20 0.57
HTR2A P28223 1/20 0.57
HTR2C P28335 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3031642 0.90 LMNA (0.61) LMNAHTR7P2RX7MEN1MLNR
SCHEMBL11507327 0.80 LMNA (0.60) LMNAHTR7P2RX7MEN1MLNR
SCHEMBL11507337 0.80 HTR7 (0.62) LMNAHTR7P2RX7MEN1MLNR
SCHEMBL11506921 0.80 LMNA (0.60) LMNAHTR7P2RX7MEN1MLNR
SCHEMBL11119055 0.80 LMNA (0.97) LMNAHTR7P2RX7MEN1MLNR
SCHEMBL7807008 0.79 LMNA (0.76) LMNAHTR7P2RX7MEN1MLNR
SCHEMBL29971224 0.79 LMNA (0.76) LMNAHTR7P2RX7MEN1MLNR
SCHEMBL11040118 0.79 LMNA (0.76) LMNAHTR7P2RX7MEN1MLNR
SCHEMBL3036872 0.78 LMNA (0.67) LMNAHTR7P2RX7MEN1MLNR
SCHEMBL3036994 0.78 LMNA (0.70) LMNAHTR7P2RX7MEN1MLNR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100216840-A1 BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS ACADIA PHARMACEUTICALS INC. (US) 2010-08-26 US disclosed
US-20080070948-A1 BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS ACADIA PHARMACEUTICALS INC. (US) 2008-03-20 US disclosed
US-7300928-B2 Benzimidazolidinone derivatives as muscarinic agents ACADIA PHARMACEUTICALS, INC. (US) 2007-11-27 US disclosed
US-7291611-B2 Benzimidazolidinone derivatives as muscarinic agents ACADIA PHARMACEUTICALS INC. (US) 2007-11-06 US disclosed
US-20060199799-A1 Benzimidazolidinone derivatives as muscarinic agents KELLY NICHOLAS M 2006-09-07 US disclosed
US-20060025402-A1 Benzimidazolidinone derivatives as muscarinic agents KELLY NICHOLAS M 2006-02-02 US disclosed
US-6951849-B2 Benzimidazolidinone derivatives as muscarinic agents ACADIA PHARMACEUTICALS INC. (US) 2005-10-04 US disclosed
US-20040067931-A1 Benzimidazolidinone derivatives as muscarinic agents ACADIA PHARMACEUTICALS INC. 2004-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080070948-A1 BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS CHRM4, CHRM1, CHRM2 LMNA 3610/4885HTR7 104/4885P2RX7 679/4885
US-20100216840-A1 BENZIMIDAZOLIDINONE DERIVATIVES AS MUSCARINIC AGENTS CHRM4, CHRM1, CHRM2 LMNA 3610/4885HTR7 104/4885P2RX7 679/4885
US-20060025402-A1 Benzimidazolidinone derivatives as muscarinic agents CHRM4, CHRM1, CHRM2 LMNA 3610/4885HTR7 104/4885P2RX7 679/4885
US-20040067931-A1 Benzimidazolidinone derivatives as muscarinic agents CHRM4, CHRM5, CHRM1 LMNA 3578/4885HTR7 100/4885P2RX7 889/4885
US-20060199799-A1 Benzimidazolidinone derivatives as muscarinic agents CHRM4, CHRM1, CHRM2 LMNA 3610/4885HTR7 104/4885P2RX7 679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.